Close

News

Biovaxy’s Enters Major Bioproduction Agreement With WuXi Biologics to Synthesize Proteins for Its Sars-CoV-2 Vaccine and Covid-T Immunodiagnostic Programs

BioVaxys Technology Corp., the world leader in haptenized protein vaccines for antiviral and cancer applications, announced today that it has entered into a major bioproduction agreement with WuXi Biologics Limited (“WuXi”), a leading global Contract Development and Research Organization...

Takeda and IDT Support Manufacturing of Johnson & Johnsons COVID-19 Vaccine

Takeda Pharmaceutical Company Limited announced a mutual agreement with IDT Biologika GmbH, a contract development and manufacturing organization, to utilize capacity at IDT previously reserved for Takeda’s dengue vaccine candidate (TAK-003) to manufacture the single-shot COVID-19 vaccine developed by...

Waters and TetraScience Partner to Deliver New Levels of Data Access and Insights with Empower Data Science Link

Waters Corporation announced it has entered a reseller agreement with TetraScience, a cloud technology innovator powering transformational changes in life sciences R&D. Through the partnership, Waters will now offer its customers the Empower™ Data Science Link, powered by TetraScience....

Elsevier and LexisNexis Collaborate to Increase Access to Patent Information in Pharma and Chemical R&D Workflows

Elsevier, a global leader in research publishing and information analytics, announced a new collaboration with LexisNexis Legal & Professional to strengthen the existing patent coverage in Reaxys®, its information solution for chemistry R&D. This integration gives companies and researchers...

Insilicos Chemistry42 AI system integrated into UCBs drug discovery programs

Insilico Medicine, an AI drug discovery company, announced that UCB will integrate Insilico's Chemistry42™ into UCB's internal drug discovery pipeline. UCB's early adoption of Insilico Medicine's proprietary technology will provide UCB's scientists with the ability to design novel hit...

Poxel Announces Completion of Arbitration with Merck Serono

POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), announced the completion of its arbitration1 with Merck Serono. The arbitral tribunal dismissed the majority of Merck...

Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in UK and South Africa Trials

Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced final efficacy of 96.4% against mild, moderate and severe disease caused by the original COVID-19 strain in a pivotal Phase 3 trial in the United Kingdom...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »